上尿路尿路上皮癌中变异组织学诊断对生存的影响
该研究回顾性分析1995年1月至2018年12月在本机构因上尿路尿路上皮癌行肾输尿管切除术的705例患者,其中47例(6.7%)有变异组织学。变异组织学与更差的癌症特异性生存(HR 2.14,95%CI 1.33-3.44,p=0.002)和总生存(HR 1.74,95%CI 1.15-2.63,p=0.008)相关。调整病理T分期后,变异组织学与癌症特异性生存(HR 1.17,95%CI 0.72-1.89,p=0.5)和总生存(HR 1.20,95%CI 0.79-1.84,p=0.4)无显著关联。
要点
- 705例上尿路尿路上皮癌患者中47例(6.7%)有变异组织学,其患病率随时间增加(p=0.003)。
- 变异组织学患者更可能接受新辅助化疗(38% vs 15%,p<0.001),也更可能有更高的病理T分期(p<0.001)。
- 调整病理T分期后,变异组织学与癌症特异性生存和总生存无显著关联。
核心结论
- 变异组织学上尿路尿路上皮癌与晚期阶段和较差生存相关,在病理分期未知时可作为高风险疾病的生物标志物。
- 变异组织学患者较差的癌症特异性生存和总生存可由肾输尿管切除术时更高的肿瘤分期解释。
- 因此,手术病理发现变异组织学并不提供超出分期的额外预后信息。
研究设计与样本
- 回顾性研究,纳入1995年1月至2018年12月在本机构因上尿路尿路上皮癌行肾输尿管切除术的705例患者。
- 采用多变量Cox模型分别检验变异组织学与癌症特异性生存和总生存的关联,并调整病理分期。
主要发现
- 47例患者(6.7%)有变异组织学,其患病率随时间增加(p=0.003)。
- 变异组织学组与纯尿路上皮癌组在其他人口学和手术特征方面相似。
- 变异组织学患者更可能接受新辅助化疗(38% vs 15%,p<0.001),也更可能有更高的病理T分期(p<0.001)。
- 变异组织学与更差的癌症特异性生存显著相关(HR 2.14;95%CI 1.33,3.44;p=0.002)。
- 变异组织学与更差的总生存显著相关(HR 1.74;95%CI 1.15,2.63;p=0.008)。
关键数值与推荐
- 调整病理T分期后,变异组织学与癌症特异性生存无显著关联(HR 1.17;95%CI 0.72,1.89;p=0.5)。
- 调整病理T分期后,变异组织学与总生存无显著关联(HR 1.20;95%CI 0.79,1.84;p=0.4)。
临床怎么用
- 原文结论指出变异组织学在病理分期未知时可作为高风险疾病的生物标志物,但手术病理发现变异组织学不提供超出分期的额外预后信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Little is known regarding the prognostic implications of variant histology in upper tract urothelial carcinoma (UTUC). We sought to evaluate the impact of variant histology UTUC on patient survival outcomes at our institution. MATERIALS AND METHODS: We identified 705 patients who underwent nephroureterectomy for UTUC at our institution between January 1995 and December 2018. We tested the association between variant histology and cancer-specific survival (CSS) and overall survival (OS) using separate multivariable Cox models after adjusting for pathological stage. RESULTS: Forty-seven patients (6.7%) had variant histology, with prevalence increasing over time (p=0.003). Other demographic and surgical characteristics were similar between variant histology and pure urothelial carcinoma groups. While patients with variant histology were more likely to receive neoadjuvant chemotherapy (38% vs 15%, p <0.001), they were also more likely to have a higher pathological T stage (p <0.001). Variant histology was associated with significantly worse CSS (HR: 2.14; 95% CI 1.33, 3.44; p=0.002) and OS (HR: 1.74; 95% CI 1.15, 2.63; p=0.008). After adjusting for pathological T stage, variant histology was not significantly associated with CSS (HR: 1.17; 95% CI 0.72, 1.89; p=0.5) or OS (HR: 1.20; 95% CI 0.79, 1.84; p=0.4). CONCLUSIONS: Variant histology UTUC is associated with advanced stage and poor survival, and could serve as a useful biomarker for high-risk disease when pathological stage is unknown. However, the inferior CSS and OS with variant histology can be explained by the higher tumor stage on nephroureterectomy. Thus, finding variant histology on surgical pathology does not provide additional prognostic information beyond stage.
引用
- Nogueira LM, Yip W, Assel MJ, et al. Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma. J Urol. 2022. PMID: 35686817. doi:10.1097/JU.0000000000002799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。